Up to one-third of patients with early, hormone-dependent, HER2-positive breast cancer experience disease recurrence. Meanwhile, including one of the CDK4/6 inhibitors in their therapy can reduce the risk of recurrence by as much as 34 percent. This is a chance for patients to be completely cured. - If we reduce the risk of recurrence in our patients at an early stage, the cancer won't spread and they won't have to be treated later for advanced disease, comments Dr. Joanna Kufel-Grabowska of the Department of Oncology and Radiotherapy at the Medical University of Gdansk, MD.
Early breast cancer is diagnosed in more than 90 percent of all patients diagnosed with breast cancer. A high percentage of patients, up to 30 percent, experience recurrences, which most often occur as distant metastases - to the liver or bone. These make the disease incurable. The standard of care for early breast cancer is now perioperative treatment.
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
